Side-by-side · Research reference

BPC-157vsCartalax

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED9/53 cited

BAnimal-MechanisticHUMAN-REVIEWED10/32 cited

BPC-157

Stable Gastric Pentadecapeptide · Healing

250–500 mcgDaily doseHwang 2016

Phase 2Evidence levelHwang 2016 Sikiric 2018

~30 minHalf-life (est.)

SQ or IM · Local · Once or twice daily

Cartalax

Bioregulator Peptide · Khavinson School

CartilagePrimary tissuePovorozniuk 2007

MSC → ChondrocyteDifferentiation axisLinkova 2023

BMD ↑Bone density effectPovorozniuk 2007

SQ · Protocol Unspecified

01Mechanism of Action

Parameter

BPC-157

Cartalax

Primary target

VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2011 Sikiric 2018

Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023

Pathway

Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2011

Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023

Downstream effect

Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018

Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023 Povorozniuk 2007

Feedback intact?

No known endogenous receptor; mechanism still under investigation

—

Origin

Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018

Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007

Antibody development

—

02Dosage Protocols

Parameter

BPC-157

Cartalax

Standard dose

250–500 mcg / dayHwang 2016

Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.

—

Frequency

Once or twice daily

Split dosing reported anecdotally for chronic injury.

—

Lower / starter dose

200 mcg / day

Conservative starter for new users.

—

Evidence basis

Animal-strong + Phase 2 clinicalSikiric 2018 Hwang 2016

Animal mechanistic studies only

Duration

2–4 weeks (acute injury); 4–8 weeks (chronic)

Anecdotal; no long-term human safety data.

—

Reconstitution

Bacteriostatic water, 1–2 mL

—

Timing

Local SQ to injury site preferred (anecdotal)

Systemic SQ also used; oral bioavailability shown in animal studies.

—

Half-life

~30 min plasma (estimated)

Tissue half-life longer; mechanism may explain durable effect.

—

Animal model dose

—

Unspecified (cartilaginous tissue extract protocol)

Rat study; extract preparation details not indexed in available abstracts.

Human dosing

—

Not established in PubMed-indexed literature

Russian-tradition protocols exist but lack peer-reviewed Western validation.

03Metabolic / Fat Loss Evidence

Parameter

BPC-157

Cartalax

Fat loss evidence

—

None — primary target is cartilage and bone tissue, not adipose

04Side Effects & Safety

Parameter

BPC-157

Cartalax

Injection site reaction

Mild irritation (anecdotal)

—

GI symptoms

None reported in PL-14736 Phase 2

—

Cardiovascular

Not reported

—

Cancer risk

Theoretical concern via VEGF angiogenesis pathwaySikiric 2018

—

Antibody formation

No data (no long-term human trials)

—

Pregnancy / OB

Avoid — insufficient safety data

—

Long-term safety

Unknown beyond Phase 2 trial duration

—

Drug interactions

None established

—

Documented adverse effects

—

None reported in indexed animal studies

Human safety data

—

Not available in PubMed-indexed literature

Absolute Contraindications

BPC-157

·Pregnancy / breastfeeding
·Known active malignancy (theoretical VEGF concern)

Cartalax

·Unknown due to lack of human clinical trial data

Relative Contraindications

BPC-157

·History of cancer
·Concurrent VEGF inhibitor therapy (theoretical)
·Acute thrombotic events

Cartalax

·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)

05Administration Protocol

Parameter

BPC-157

Cartalax

1. Reconstitution

Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.

Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.

2. Injection site

Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.

Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.

3. Timing

No strict timing requirement. Most users dose once or twice daily, often morning + evening.

Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.

—

5. Needle

27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.

—

06Stack Synergy

BPC-157

+ TB-500

Strong

View TB-500 →

BPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.

BPC-157: 250–500 mcg SQ · daily
TB-500: 2 mg SQ · 2× per week
Primary benefit: Tendon/ligament/muscle repair via complementary angiogenesis + migration

Cartalax

— no documented stacks